TSHA

TSHA is a clinical-stage biotech where the financials describe a research engine, not a business: FY2025 'revenue' of $9.77M is immaterial collaboration/grant income, so the headline P/S of 197.8 is meaningless — the $1.93B market cap is a bet on the pipeline, not the income statement. Operating losses are structural and widening (operating income -$110M, R&D up 30.9% to $86.4M, operating cash burn -$93.1M), and the accumulated deficit sits at -$711M. The one thing the numbers do tell you clearly is survivability: a $320M cash pile (+130% YoY after raising), $325M current assets against just $26.6M current liabilities, only $50.1M long-term debt, and equity rebuilt to $247M. At ~$93M annual burn that funds roughly three years of operations — long enough to reach the catalysts that matter.

The value sits entirely in TSHA-102 for Rett syndrome, and the MD&A reads encouragingly: all 12 Part A REVEAL patients gained or regained ≥1 developmental milestone, with no treatment-related serious adverse events or dose-limiting toxicities across both Part A and the pivotal trial as of the March 2026 cutoff. Rett has no approved disease-modifying therapy, the REVEAL pivotal (Part B) is dosing with FDA-aligned protocol and SAP, and a 6-month interim analysis 'may serve as the basis for BLA submission' — a credible, near-term path to regulatory filing on a single trial. That FDA-blessed extrapolation design is the bull case.